-
Autor
Akdeniz, Delal 1 Andrieu, Nadine 1 Antoniou, Antonis C 1 Ausems, Margreet G E M 1 Brewer, Carole 1 Dommering, Charlotte J 1 Easton, Douglas F 1 Engel, Christoph 1 Evans, D Gareth 1 Foretová, Lenka 1 Frost, Debra 1 Gómez-García, Encarnacion B 1 Heemskerk-Gerritsen, Bernadette A M 1 Hooning, Maartje J 1 Izatt, Louise 1 Jager, Agnes 1 Jakubowska, Anna 1 Kast, Karin 1 Mooij, Thea M 1 Noguès, Catherine 1
- Organizace
-
Pracoviště
Center of Familial Breast and Ovarian... 1 Centre for Cancer Genetic Epidemiolog... 1 Centre for Cancer Genetic Epidemiolog... 1 Centre for Personalized Response Moni... 1 Department for Clinical Genetics Radb... 1 Department of Cancer Epidemiology and... 1 Department of Clinical Genetics Amste... 1 Department of Clinical Genetics Guy's... 1 Department of Clinical Genetics Leide... 1 Department of Clinical Genetics Odens... 1 Department of Clinical Genetics Royal... 1 Department of Clinical Research Unive... 1 Department of Epidemiology University... 1 Department of Genetics Maastricht Uni... 1 Department of Genetics and Pathology ... 1 Department of Medical Genetics Nation... 1 Department of Medical Oncology Erasmu... 1 Department of Molecular Genetics Nati... 1 Department of Obstetrics and Gynecolo... 1 Department of Radiotherapy Erasmus MC... 1
- Formát
- Publikační typ
- Check Tag
- Kategorie
- Jazyk
- Země
- Časopis/zdroj
- Dostupnost
- Vlastník
-
Autor
Akdeniz, Delal 1 Andrieu, Nadine 1 Antoniou, Antonis C 1 Ausems, Margreet G E M 1 Brewer, Carole 1 Dommering, Charlotte J 1 Easton, Douglas F 1 Engel, Christoph 1 Evans, D Gareth 1 Foretová, Lenka 1 Frost, Debra 1 Gómez-García, Encarnacion B 1 Heemskerk-Gerritsen, Bernadette A M 1 Hooning, Maartje J 1 Izatt, Louise 1 Jager, Agnes 1 Jakubowska, Anna 1 Kast, Karin 1 Mooij, Thea M 1 Noguès, Catherine 1
- Organizace
-
Pracoviště
Center of Familial Breast and Ovarian... 1 Centre for Cancer Genetic Epidemiolog... 1 Centre for Cancer Genetic Epidemiolog... 1 Centre for Personalized Response Moni... 1 Department for Clinical Genetics Radb... 1 Department of Cancer Epidemiology and... 1 Department of Clinical Genetics Amste... 1 Department of Clinical Genetics Guy's... 1 Department of Clinical Genetics Leide... 1 Department of Clinical Genetics Odens... 1 Department of Clinical Genetics Royal... 1 Department of Clinical Research Unive... 1 Department of Epidemiology University... 1 Department of Genetics Maastricht Uni... 1 Department of Genetics and Pathology ... 1 Department of Medical Genetics Nation... 1 Department of Medical Oncology Erasmu... 1 Department of Molecular Genetics Nati... 1 Department of Obstetrics and Gynecolo... 1 Department of Radiotherapy Erasmus MC... 1
- Formát
- Publikační typ
- Check Tag
- Kategorie
- Jazyk
- Země
- Časopis/zdroj
- Dostupnost
- Vlastník
Open Access Digital Library od 1996-01-01
PubMed
37369040
DOI
10.1093/jnci/djad116
Knihovny.cz E-zdroje
BACKGROUND: Radiation-induced secondary breast cancer (BC) may be a concern after radiation therapy (RT) for primary breast cancer (PBC), especially in young patients with germline (g)BRCA-associated BC who already have high contralateral BC (CBC) risk and potentially increased genetic susceptibility to radiation. We sought to investigate whether adjuvant RT for PBC increases the risk of CBC in patients with gBRCA1/2-associated BC. METHODS: The gBRCA1/2 pathogenic variant carriers diagnosed with PBC were selected from the prospective International BRCA1/2 Carrier Cohort Study. We used multivariable Cox proportional hazards models to investigate the association between RT (yes vs no) and CBC risk. We further stratified for BRCA status and age at PBC diagnosis (<40 and >40 years). Statistical significance tests were 2-sided. RESULTS: Of 3602 eligible patients, 2297 (64%) received adjuvant RT. Median follow-up was 9.6 years. The RT group had more patients with stage III PBC than the non-RT group (15% vs 3%, P < .001), received chemotherapy more often (81% vs 70%, P < .001), and received endocrine therapy more often (50% vs 35%, P < .001). The RT group had an increased CBC risk compared with the non-RT group (adjusted hazard ratio [HR] = 1.44; 95% confidence interval [CI] = 1.12 to 1.86). Statistical significance was observed in gBRCA2 (HR = 1.77; 95% CI = 1.13 to 2.77) but not in gBRCA1 pathogenic variant carriers (HR = 1.29; 95% CI = 0.93 to 1.77; P = .39 for interaction). In the combined gBRCA1/2 group, patients irradiated when they were younger than or older than 40 years of age at PBC diagnosis showed similar risks (HR = 1.38; 95% CI = 0.93 to 2.04 and HR = 1.56; 95% CI = 1.11 to 2.19, respectively). CONCLUSIONS: RT regimens minimizing contralateral breast dose should be considered in gBRCA1/2 pathogenic variant carriers.
- MeSH
- kohortové studie MeSH
- lidé MeSH
- nádory prsu * genetika radioterapie farmakoterapie MeSH
- prospektivní studie MeSH
- protein BRCA1 genetika MeSH
- protein BRCA2 genetika MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
Sdílet
Název dokumentu
Po ukončení testovacího provozu bude odkaz přesměrován adresu produkční verze portálu Medvik.